Molecular interventions that limit pathogenic CNS inflammation are used to treat
autoimmune conditions such as multiple sclerosis (MS). Remarkably, IL-1β–knockout mice …

A large body of data indicates that multiple sclerosis (MS) is an autoimmune disease which
is initiated by CD4+ T-helper 1 (Th1) and Th17 cells that are reactive against proteins in the …

Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to
middle-aged adults, affecting~ 2.5 million people worldwide. Currently, most therapeutics for …

The pathology in neurodegenerative diseases is often accompanied by inflammation. It is
well-known that many cells within the central nervous system (CNS) also contribute to …

Emerging data point to important contributions of both autoimmune inflammation and
progressive degeneration in the pathophysiology of multiple sclerosis (MS). Unfortunately …

Multiple sclerosis (MS) is the prototypical inflammatory disease of the central nervous
system (CNS). MS lesions harbor different immune cells, but the contribution of individual …

We performed unbiased, comprehensive immunophenotyping of cerebrospinal fluid (CSF)
and blood leukocytes in 221 subjects referred for the diagnostic work-up of …

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system,
usually occurring in young adults and leading to disability. Despite the progress in …

Background Multiple sclerosis (MS) is an autoimmune, neuroinflammatory disease, with an
unclear etiology. However, T cells play a central role in the pathogenesis by crossing the …

Multiple sclerosis, the most common cause of neurological disability in young population
after trauma, represents a significant public health burden. Current challenges associated …